Amoy Diagnostics

AmoyDx's kit is designed to detect hotspot mutations/fusions in nine genes to help guide treatment decisions for non-small cell lung cancer patients.

The companion diagnostic for Pfizer's Xalkori identifies 14 ROS1 gene fusions by analyzing tumor messenger RNA from human tumor tissue or body fluids.

AmoyDx's molecular diagnostics tests, powered by its ADx-ARMS and Super-ARMS technologies, will be made available in Hong Kong and Macau.

The real-time PCR-based test is designed to identify EGFR mutations in circulating tumor DNA in plasma samples.

Amoy will supply its CD95 IHC and CpG2 qPCR kits to develop a companion diagnostic for Canbridge's lead product targeting recurrent glioblastoma multiforme.

The firm's ROS1 gene fusion kit was approved as a companion diagnostic for Pfizer's Xalkori.

The test, which will be based on AmoyDx's proprietary real-time PCR technology, will identify cancer-associated mutations in the RAS gene family.

AmoyDx will develop and commercialize a series of oncology tests that use Illumina NGS technology, including the firm's TruSight Tumor 15 panel.

NEW YORK (GenomeWeb) — Chinese molecular diagnostics firm Amoy Diagnostics said today that four of its mutation analysis kits have received CE marking.

NEW YORK (GenomeWeb) – MoBiTec today announced a deal for the distribution of Amoy Diagnostics products in Germany.

Pages

New results from the NASA Twins Study indicate that the immune system may rev up when in space, the Washington Post reports.

Kelvin Droegemeier, the new science advisor, spoke at the American Association for the Advancement of Science meeting, Geekwire reports.

In PNAS this week: whole-genome assembly for the white shark, paper-based microfluidic method for detecting the malaria parasite, and more.

The World Health Organization has announced the members of its gene-editing committee, according to NPR.